ES2581978T3 - Un método de presensibilización de cánceres antes de radioterapia y/o quimioterapia y una nueva mezcla de citoquinas - Google Patents

Un método de presensibilización de cánceres antes de radioterapia y/o quimioterapia y una nueva mezcla de citoquinas Download PDF

Info

Publication number
ES2581978T3
ES2581978T3 ES05789138.4T ES05789138T ES2581978T3 ES 2581978 T3 ES2581978 T3 ES 2581978T3 ES 05789138 T ES05789138 T ES 05789138T ES 2581978 T3 ES2581978 T3 ES 2581978T3
Authority
ES
Spain
Prior art keywords
free
interleukin
mixture
ratio
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05789138.4T
Other languages
English (en)
Spanish (es)
Inventor
Eyal Talor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cel Sci Corp
Original Assignee
Cel Sci Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cel Sci Corp filed Critical Cel Sci Corp
Application granted granted Critical
Publication of ES2581978T3 publication Critical patent/ES2581978T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES05789138.4T 2004-06-29 2005-06-28 Un método de presensibilización de cánceres antes de radioterapia y/o quimioterapia y una nueva mezcla de citoquinas Expired - Lifetime ES2581978T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US878563 1997-06-19
US10/878,563 US20050002899A1 (en) 2003-07-03 2004-06-29 Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
PCT/US2005/022678 WO2006004633A2 (en) 2004-06-29 2005-06-28 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture

Publications (1)

Publication Number Publication Date
ES2581978T3 true ES2581978T3 (es) 2016-09-08

Family

ID=35783284

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05789138.4T Expired - Lifetime ES2581978T3 (es) 2004-06-29 2005-06-28 Un método de presensibilización de cánceres antes de radioterapia y/o quimioterapia y una nueva mezcla de citoquinas

Country Status (8)

Country Link
US (1) US20050002899A1 (https=)
EP (1) EP1773368B1 (https=)
JP (1) JP5122279B2 (https=)
CN (1) CN101014354A (https=)
AU (1) AU2005260053A1 (https=)
CA (1) CA2571598A1 (https=)
ES (1) ES2581978T3 (https=)
WO (1) WO2006004633A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
CA2593648A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CN100344325C (zh) * 2005-10-17 2007-10-24 华南师范大学 一种治疗宫颈癌的药物及其制备方法与应用
US20080131396A1 (en) * 2006-12-04 2008-06-05 Cel-Sci Corp. Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
CN102166347B (zh) * 2011-04-02 2013-12-11 广州市恺泰生物科技有限公司 一种白细胞介素-12的药物新用途
WO2025019822A1 (en) * 2023-07-19 2025-01-23 Istari Oncology, Inc. Methods of treatment with a chimeric poliovirus in patients with glioblastoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789588B1 (en) * 1994-11-17 2005-01-19 University Of South Florida Method for making a medicament for treating secondary immunodeficiency
AU2002232560A1 (en) * 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture

Also Published As

Publication number Publication date
WO2006004633A2 (en) 2006-01-12
CA2571598A1 (en) 2006-01-12
AU2005260053A1 (en) 2006-01-12
CN101014354A (zh) 2007-08-08
US20050002899A1 (en) 2005-01-06
JP2008505082A (ja) 2008-02-21
JP5122279B2 (ja) 2013-01-16
EP1773368B1 (en) 2016-05-04
EP1773368A2 (en) 2007-04-18
WO2006004633A3 (en) 2006-03-16
EP1773368A4 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
CN1845757B (zh) 细胞因子混合物在制备由于预敏化癌症的药物中的用途和用于治疗癌症的药物组合物
CA2694428C (en) Compositions and methods for treatment of advanced prostate cancer
US20070166279A1 (en) Method for modulating hla class ii tumor cell surface expression with a cytokine mixture
CN1379664A (zh) 利用活性氧代谢物抑制剂活化和保护细胞毒性淋巴细胞
ES2553133T3 (es) Método de modificación de la proporción de CD4/CD8 y del infiltrado celular mononuclear en un tumor
ES2581978T3 (es) Un método de presensibilización de cánceres antes de radioterapia y/o quimioterapia y una nueva mezcla de citoquinas
US20080131396A1 (en) Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
HK1105858A (en) A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
HK1096846A (en) A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
WO2006101535A1 (en) Inhibition of proteasome function to potentiate the proapoptotic and antitumor activity of cytokines
Kalanjiam et al. A new alternative cancer treatment modality: Immunotherapy
HK1106983A (en) A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
HK1193755A (en) A composition for treatment of advanced prostate cancer
HK1120214A (en) A method for modulating hla class ii tumor cell surface expression with a cytokine mixture